IRCT201105026361N1已完成2 期
Comparing the treatment effect of Pioglitazone with Metformin in patients with Non Alcoholic SteatoHepatitis (NASH)
Vice chancellor for research, Kashan University of Medical Sciences and Health Services0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 21 years 至 50 years（—）
- 性别
- All
入选标准
- •All patients with fatty liver disease based on sonography that have Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) more than normal (more than 40). Exclusion criteria: Alcohol consumption; drug induced hepatitis; use of some drugs (corticosteroids, statins); Diabetes mellitus; Chronic viral hepatitis (B,C); Autoimmune hepatitis; Wilson disease; Hemochromatosis; Ischemic heart disease; Heart failure; Liver failure; liver mass; Pregnancy.
排除标准
- 未提供
研究者
相似试验
招募中
3 期
Effect of Pioglitazone and ClobetasolIRCT20210926052596N1Tehran University of Medical Sciences40
招募中
3 期
comparison the teraputic effect of pioglitazone and carnitine to metformin and carnitine in patients with non alcoholic fatty liver diseasenon alcoholic fatty liver disease (NAFLD).Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20190701044062N3Tabriz University of Medical Sciences80
已完成
3 期
comparison the therapeutic effect of pioglitazone and carnitine to pioglitazone and vitamin E in patients with non alcoholic fatty liver diseaseIRCT20190701044062N8Tabriz University of Medical Sciences80
进行中（未招募）
不适用
Comparison of the Effects of Pioglitazone vs. Placebo when given in addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus and Renal Failure – The PIOren Study - PIOren StudyThe study population will consist of insufficiently controlled patients with type 2 diabetes with renal failure requiring dialysisMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2007-006744-21-DETakeda Pharma GmbH
进行中（未招募）
不适用
Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk and an activated inflammationA randomized double-blinded phase II studyon-diabetic hypertensive patients with a hsCRP value > 1.0 mg/L < 10.0 mg/L and pretreated with ACE inhibitors for at least 12 weeks are eligible for study participation.MedDRA version: 8.1Level: LLTClassification code 10003601Term: AtherosclerosisEUCTR2006-004028-35-DETakeda Pharma GmbH